All In Biotech

Drug Trial Radar · NCT00689104

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,336 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,336

Actual

Start

Apr 28, 2008

Primary completion

Mar 24, 2009

Study completion Mar 24, 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • MirabegronDrug

    Tablets

  • TolterodineDrug

    Capsules

  • Placebo to MirabegronDrug

    Matching mirabegron placebo tablets.

  • Placebo to TolterodineDrug

    Matching tolterodine placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 12 (final visit)
  2. Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 12

Locations

218 sites in 30 countries. Site status is shown where the registry gives one.

  • Site not named

    Auchenflower, Australia

  • Site not named

    Clayton, Australia

  • Site not named

    Kogarah, Australia

  • Site not named

    Randwick, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Minsk, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Antwerp, Belgium

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Leper, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Sint-Truiden, Belgium

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Brno, Czechia

  • Site not named

    Mělník, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Ostrava-Poruba, Czechia

  • Site not named

    Pilsen, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Štětí, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Aarhus, Denmark

  • Site not named

    Glostrup Municipality, Denmark

  • Site not named

    Roskilde, Denmark

  • Site not named

    Helsinki, Finland

Showing 40 of 218 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.